Establishment of Clinical Basis for Hematopoietic Growth Factors Therapy in Brain Injury

Launched by YONSEI UNIVERSITY · Dec 16, 2013

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment approach for patients with neurological diseases, such as stroke, cerebral palsy, and atypical Parkinson's disease. Researchers want to see if combining two medications, erythropoietin (EPO) and granulocyte-colony stimulating factors (G-CSF), can help repair damage in the brain and protect it from further injury. The goal is to find out if this combination therapy is safe and effective, especially for patients who have had these conditions for at least three months and have previously received EPO and G-CSF injections at least six months ago.

To participate in this trial, you need to be over 20 years old and able to give your consent. The study is currently recruiting participants, and it aims to create a better understanding of how this treatment can support recovery in people with neurological conditions. If eligible, participants can expect to receive the combination therapy and be monitored for its effects. It's important to note that certain health conditions and medications may prevent some individuals from participating in the trial.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Over 20 years old
• • Voluntary participants
• • Neurological diseases including stroke, cerebral palsy, or atypical parkinsonism, at least 3 months after their onset
• • Participants who got previous EPO+GCSF injection at least 6 months ago.
• Exclusion Criteria:
• • Under 20 years old
• • Participants who can not voluntarily consent
• • Encephalopathy including brain tumor and infection
• • Warfarin (coumadin) medications
• • Leukopenia, Thrombocytopenia, Polycythemia
• • Malignant diseases, Malignant hypertension, Myeloproliferative disorder, Septic embolism, Hyperkalemia
• • Hepatic or Renal dysfunction, Serum creatinine\>3mg/dl
• • Allergic reactions against to exogenous EPO and G-CSF
• • Involved in a exclusion criteria for MRI test
• • A women who is pregnant or on breast feeding
• • Body temperature over 38°C
• • Blood pressure over 140/90 mmHg at pre-treatment
• • Blood pressure over 160/100 mmHg during intervention
• • Hb \> 15 g/dL at pre-treatment
• • Hb \> 17 g/dL during intervention
• • Pneumonia detected by X-ray test
• • Recurrent history of aspiration pneumonia